A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Stopped The Sponsor made the decision to close enrollment to prioritize our efforts on TransCon IL-2 ß/g.

Conditions

• Advanced Solid Tumor
• Locally Advanced Solid Tumor
• Metastatic Solid Tumor
• Head and Neck Squamous Cell Carcinoma HNSCC
• HPV-associated Cancers
• Neoadjuvant Melanoma
• Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

Interventions

• DRUG: TransCon TLR7/8 Agonist
• DRUG: Pembrolizumab

Sponsor

Ascendis Pharma Oncology Division A/S